Absalón-Aguilar, 116 patient colchicine late treatment RCT: 29% lower mortality [p=0.74], 17% lower progression [p=0.67], and 13% worse recovery [p=0.59] https://c19p.org/absalonaguilar
copied to clipboard
Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)
et al., Journal of General Internal Medicine, doi:10.1007/s11606-021-07203-8
Very late stage RCT with 56 colchicine and 60 control patients in Mexico, showing no significant differences.
|
risk of death, 28.6% lower, RR 0.71, p = 0.74, treatment 4 of 56 (7.1%), control 6 of 60 (10.0%), NNT 35.
|
|
progression to critical or death, 17.0% lower, OR 0.83, p = 0.67, treatment 56, control 60, primary outcome, RR approximated with OR.
|
|
risk of no recovery, 13.0% higher, RR 1.13, p = 0.59, treatment 56, control 60, Kaplan–Meier.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Absalón-Aguilar et al., 11/9/2021, Double Blind Randomized Controlled Trial, placebo-controlled, Mexico, North America, peer-reviewed, 18 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.